Long-acting anti-inflammatory injectable DEX-Gel with sustained release and self-healing properties regulates T_H1/T_H2 immune balance for minimally invasive treatment of allergic rhinitis.

ABSTRACT:

Background

Allergic rhinitis (AR) is a prevalent immune-related allergic disease, and corticosteroid nasal sprays serve as the primary treatment for this patient population. However, their short duration of efficacy and frequent administration pose challenges, leading to drug wastage and potential adverse effects. To overcome these limitations, we devised a novel approach to formulate DEX-Gel by incorporating dexamethasone (DEX) into a blend of Pluronic F127, stearic acid (SA), and polyethylene glycol 400 (PEG400) to achieve sustained-release treatment for AR.

Results

Following endoscopic injection into the nasal mucosa of AR rats, DEX-Gel exhibited sustained release over a 14-day period. In vivo trials employing various assays, such as flow cytometry (FC), demonstrated that

SUBMITTER: Dai L 

PROVIDER: S-EPMC10845556 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature